Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors following Disease Progression or Relapse

Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors following Disease Progression or Relapse

Immune checkpoint inhibitors (ICIs) are at the forefront of advanced non-small-cell lung cancer (NSCLC) treatment. Still, only 27–46% of patients respond to initial therapy with ICIs, and of those, up to 65% develop resistance within four years. After disease progression (PD), treatment options are...

Full description

Bibliographic Details
Main Authors: Maria Effrosyni Livanou, Vasiliki Nikolaidou, Vasileios Skouras, Oraianthi Fiste, Elias Kotteas
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Cancers
Subjects:
immunotherapy
immune checkpoint inhibitors
rechallenge therapy
resistance
NSCLC
Online Access:https://www.mdpi.com/2072-6694/16/6/1196

Internet

https://www.mdpi.com/2072-6694/16/6/1196

Similar Items